{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T17:30:28Z","timestamp":1763141428723,"version":"3.37.3"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s13300-020-00925-8","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T05:02:22Z","timestamp":1601010142000},"page":"2555-2593","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The Safety and Efficacy of Second-Generation Basal Insulin Analogues in Adults with Type 2 Diabetes at Risk of Hypoglycemia and Use in Other Special Populations: A Narrative Review"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2729-606X","authenticated-orcid":false,"given":"Alice Y. Y.","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jencia","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Freemantle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shamasunder H.","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elif","family":"Ekinci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,25]]},"reference":[{"issue":"12","key":"925_CR1","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1007\/s00125-018-4729-5","volume":"61","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61(12):2461\u201398.","journal-title":"Diabetologia"},{"issue":"3","key":"925_CR2","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s13300-018-0413-5","volume":"9","author":"L Blonde","year":"2018","unstructured":"Blonde L, Meneghini L, Peng XV, et al. Probability of achieving glycemic control with basal insulin in patients with type 2 diabetes in real-world practice in the USA. Diabetes Ther. 2018;9(3):1347\u201358.","journal-title":"Diabetes Ther"},{"issue":"3","key":"925_CR3","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/dom.13132","volume":"20","author":"D Russell-Jones","year":"2018","unstructured":"Russell-Jones D, Pouwer F, Khunti K. Identification of barriers to insulin therapy and approaches to overcoming them. Diabetes Obes Metab. 2018;20(3):488\u201396.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"925_CR4","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1001\/jamainternmed.2014.136","volume":"174","author":"AI Geller","year":"2014","unstructured":"Geller AI, Shehab N, Lovgrove MC, et al. National estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizations. JAMA Intern Med. 2014;174(5):678\u201386.","journal-title":"JAMA Intern Med"},{"key":"925_CR5","doi-asserted-by":"crossref","first-page":"f4533","DOI":"10.1136\/bmj.f4533","volume":"347","author":"A Goto","year":"2013","unstructured":"Goto A, Arah OA, Goto M, et al. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ. 2013;347:f4533.","journal-title":"BMJ."},{"issue":"15","key":"925_CR6","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1056\/NEJMoa1003795","volume":"363","author":"S Zoungas","year":"2010","unstructured":"Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363(15):1410\u20138.","journal-title":"N Engl J Med"},{"issue":"3","key":"925_CR7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1464-5491.2007.02341.x","volume":"25","author":"SA Amiel","year":"2008","unstructured":"Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in type 2 diabetes. Diabet Med. 2008;25(3):245\u201354.","journal-title":"Diabet Med"},{"issue":"2","key":"925_CR8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1001\/jamainternmed.2013.12956","volume":"174","author":"ES Huang","year":"2014","unstructured":"Huang ES, Laiteerapong N, Liu JY, et al. Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study. JAMA Intern Med. 2014;174(2):251\u20138.","journal-title":"JAMA Intern Med."},{"key":"925_CR9","doi-asserted-by":"crossref","first-page":"b5444","DOI":"10.1136\/bmj.b5444","volume":"340","author":"ME Miller","year":"2010","unstructured":"Miller ME, Bonds DE, Gerstein HC, et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ. 2010;340:b5444.","journal-title":"BMJ"},{"issue":"1","key":"925_CR10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/2251-6581-11-17","volume":"11","author":"G Shafiee","year":"2012","unstructured":"Shafiee G, Mohajeri-Tehrani M, Pajouhi M, Larijani B. The importance of hypoglycemia in diabetic patients. J Diabetes Metab Disord. 2012;11(1):17.","journal-title":"J Diabetes Metab Disord"},{"issue":"1","key":"925_CR11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jama.2017.7117","volume":"318","author":"C Wysham","year":"2017","unstructured":"Wysham C,\u00a0 Bhargava A, Chaykinet L, et al. Effect of insulin degludec vs insulin glargine u100 on hypoglycemia in patients with type 2 diabetes: the SWITCH 2 randomized clinical trial. JAMA. 2017;318(1):45\u201356.","journal-title":"JAMA"},{"issue":"6","key":"925_CR12","doi-asserted-by":"crossref","first-page":"423","DOI":"10.4093\/dmj.2016.40.6.423","volume":"40","author":"JS Yun","year":"2016","unstructured":"Yun JS, Ko SH. Risk factors and adverse outcomes of severe hypoglycemia in type 2 diabetes mellitus. Diabetes Metab J. 2016;40(6):423\u201332.","journal-title":"Diabetes Metab J"},{"issue":"5","key":"925_CR13","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1210\/jc.2009-2828","volume":"95","author":"TM Davis","year":"2010","unstructured":"Davis TM, Brown SGA, Jacobs IG, et al. Determinants of severe hypoglycemia complicating type 2 diabetes: the Fremantle diabetes study. J Clin Endocrinol Metab. 2010;95(5):2240\u20137.","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"925_CR14","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/dom.12416","volume":"17","author":"RH Becker","year":"2015","unstructured":"Becker RH, Nowotny I, Teichert L, et al. Low within- and between-day variability in exposure to new insulin glargine 300 U\/ml. Diabetes Obes Metab. 2015;17(3):261\u20137.","journal-title":"Diabetes Obes Metab."},{"issue":"4","key":"925_CR15","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2337\/dc16-0684","volume":"40","author":"RM Bergenstal","year":"2017","unstructured":"Bergenstal RM, Bailey TS, Rodbard D, et al. Comparison of insulin glargine 300 units\/mL and 100 units\/mL in adults with type 1 diabetes: continuous glucose monitoring profiles and variability using morning or evening injections. Diabetes Care. 2017;40(4):554\u201360.","journal-title":"Diabetes Care"},{"issue":"9","key":"925_CR16","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s40262-014-0165-y","volume":"53","author":"H Haahr","year":"2014","unstructured":"Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. 2014;53(9):787\u2013800.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"925_CR17","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/j.1463-1326.2012.01638.x","volume":"14","author":"T Heise","year":"2012","unstructured":"Heise T, Nosek L, B\u00f8ttcher SG, Hastrup H, Haahret H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14(10):944\u201350.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"925_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jamcollsurg.2016.10.025","volume":"224","author":"RL Schilsky","year":"2017","unstructured":"Schilsky RL. Finding the evidence in real-world evidence: moving from data to information to knowledge. J Am Coll Surg. 2017;224(1):1\u20137.","journal-title":"J Am Coll Surg"},{"issue":"4","key":"925_CR19","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/dom.12438","volume":"17","author":"GB Bolli","year":"2015","unstructured":"Bolli GB, Riddle MC, Bergenstal RM, et al. New insulin glargine 300 U\/ml compared with glargine 100 U\/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab. 2015;17(4):386\u201394.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"925_CR20","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/dom.13515","volume":"21","author":"GB Bolli","year":"2019","unstructured":"Bolli GB, Wysham C, Fisher M, et al. A post-hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U\/mL (Gla-300) versus 100 U\/mL (Gla-100) over wider nocturnal windows in individuals with type 2 diabetes on a basal-only insulin regimen. Diabetes Obes Metab. 2019;21(2):402\u20137.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"925_CR21","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/dom.13578","volume":"21","author":"RC Bonadonna","year":"2019","unstructured":"Bonadonna RC, Yale JF, Brulle-Wohlhueter C, et al. Hypoglycaemia as a function of HbA1c in type 2 diabetes: insulin glargine 300 U\/mL in a patient-level pooled analysis of edition 1, 2 and 3. Diabetes Obes Metab. 2019;21(3):715\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"925_CR22","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00592-018-1258-0","volume":"56","author":"A Diez-Fernandez","year":"2019","unstructured":"Diez-Fernandez A, Cavero-Redondo I, Moreno-Fern\u00e1ndez J, et al. Effectiveness of insulin glargine U-300 versus insulin glargine U-100 on nocturnal hypoglycemia and glycemic control in type 1 and type 2 diabetes: a systematic review and meta-analysis. Acta Diabetol. 2019;56(3):355\u201364.","journal-title":"Acta Diabetol"},{"issue":"9825","key":"925_CR23","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(12)60205-0","volume":"379","author":"AJ Garber","year":"2012","unstructured":"Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1498\u2013507.","journal-title":"Lancet"},{"issue":"9","key":"925_CR24","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.2337\/dc12-2329","volume":"36","author":"SC Gough","year":"2013","unstructured":"Gough SC,\u00a0 Bhargava A, Jain R, et al. Low-volume insulin degludec 200 units\/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes Care. 2013;36(9):2536\u201342.","journal-title":"Diabetes Care"},{"issue":"2","key":"925_CR25","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/dom.12411","volume":"17","author":"P Hollander","year":"2015","unstructured":"Hollander P, King AB, Del Prato S, et al. Insulin degludec improves long-term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basal-bolus insulin therapy. Diabetes Obes Metab. 2015;17(2):202\u20136.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"925_CR26","doi-asserted-by":"crossref","first-page":"858","DOI":"10.2337\/dc12-1668","volume":"36","author":"L Meneghini","year":"2013","unstructured":"Meneghini L, Atkin SL, Gough SCL, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care. 2013;36(4):858\u201364.","journal-title":"Diabetes Care"},{"issue":"4","key":"925_CR27","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1185\/03007995.2013.772507","volume":"29","author":"M Monami","year":"2013","unstructured":"Monami M, Mannucci E. Efficacy and safety of degludec insulin: a meta-analysis of randomised trials. Curr Med Res Opin. 2013;29(4):339\u201342.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"925_CR28","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/jdi.12102","volume":"4","author":"Y Onishi","year":"2013","unstructured":"Onishi Y, Iwamoto Y, Yoo SJ, et al. Insulin degludec compared with insulin glargine in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, Pan-Asian, treat-to-target trial. J Diabetes Investig. 2013;4(6):605\u201312.","journal-title":"J Diabetes Investig"},{"issue":"2","key":"925_CR29","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/dom.12032","volume":"15","author":"RE Ratner","year":"2013","unstructured":"Ratner RE, Gough SCL, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013;15(2):175\u201384.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"925_CR30","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.2337\/dc14-0991","volume":"37","author":"MC Riddle","year":"2014","unstructured":"Riddle MC, Bolli GB, Ziemen M, et al. New insulin glargine 300 units\/mL versus glargine 100 units\/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care. 2014;37(10):2755\u201362.","journal-title":"Diabetes Care"},{"issue":"9","key":"925_CR31","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/dom.12485","volume":"17","author":"R Ritzel","year":"2015","unstructured":"Ritzel R, Roussel R, Bolli GB, et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U\/ml versus glargine 100 U\/ml in people with type 2 diabetes. Diabetes Obes Metab. 2015;17(9):859\u201367.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"925_CR32","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/dom.13105","volume":"20","author":"R Ritzel","year":"2018","unstructured":"Ritzel R, Bolli GB, Giaccari A, et al. Better glycaemic control and less hypoglycaemia with insulin glargine 300 U\/mL vs glargine 100 U\/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes. Diabetes Obes Metab. 2018;20(3):541\u20138.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"925_CR33","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.diabet.2017.03.001","volume":"43","author":"Y Terauchi","year":"2017","unstructured":"Terauchi Y, Koyama M, Cheng X, et al. Glycaemic control and hypoglycaemia with insulin glargine 300 U\/mL compared with glargine 100 U\/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month extension). Diabetes Metab. 2017;43(5):446\u201352.","journal-title":"Diabetes Metab"},{"issue":"4","key":"925_CR34","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/dom.12618","volume":"18","author":"Y Terauchi","year":"2016","unstructured":"Terauchi Y, Koyama M, Cheng X, et al. New insulin glargine 300 U\/ml versus glargine 100 U\/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2). Diabetes Obes Metab. 2016;18(4):366\u201374.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"925_CR35","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1007\/s13300-018-0498-x","volume":"9","author":"SM Twigg","year":"2018","unstructured":"Twigg SM, Escalada J, Stella P, et al. Association of patient profile with glycemic control and hypoglycemia with insulin glargine 300 U\/mL in type 2 diabetes: a post hoc patient-level meta-analysis. Diabetes Ther. 2018;9(5):2043\u201353.","journal-title":"Diabetes Ther"},{"issue":"2","key":"925_CR36","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s13300-014-0076-9","volume":"5","author":"J Vora","year":"2014","unstructured":"Vora J, Christensen T, Rana A, et al. Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials. Diabetes Ther. 2014;5(2):435\u201346.","journal-title":"Diabetes Ther."},{"issue":"12","key":"925_CR37","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.2337\/dc14-0990","volume":"37","author":"H Yki-Jarvinen","year":"2014","unstructured":"Yki-Jarvinen H, Bergenstal R, Ziemen M, et al. New insulin glargine 300 units\/mL versus glargine 100 units\/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care. 2014;37(12):3235\u201343.","journal-title":"Diabetes Care"},{"issue":"5","key":"925_CR38","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00592-018-1107-1","volume":"55","author":"XW Zhang","year":"2018","unstructured":"Zhang XW, Zhang XL, Xu B, et al. Comparative safety and efficacy of insulin degludec with insulin glargine in type 2 and type 1 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol. 2018;55(5):429\u201341.","journal-title":"Acta Diabetol."},{"issue":"12","key":"925_CR39","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.2337\/dc12-1205","volume":"35","author":"B Zinman","year":"2012","unstructured":"Zinman B, Philis-Tsimikas A, Cariou B, et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012;35(12):2464\u201371.","journal-title":"Diabetes Care"},{"issue":"3","key":"925_CR40","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s13300-019-0624-4","volume":"10","author":"W Zhou","year":"2019","unstructured":"Zhou W,\u00a0 Tao J, Zhou X, Chen H. Insulin degludec, a novel ultra-long-acting basal insulin versus insulin glargine for the management of type 2 diabetes: a systematic review and meta-analysis. Diabetes Ther. 2019;10(3):835\u201352. \u00a0","journal-title":"Diabetes Ther"},{"key":"925_CR41","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.diabres.2018.03.041","volume":"142","author":"RC Bonadonna","year":"2018","unstructured":"Bonadonna RC, Renard E, Cheng A, et al. Switching to insulin glargine 300 U\/mL: is duration of prior basal insulin therapy important? Diabetes Res Clin Pract. 2018;142:19\u201325.","journal-title":"Diabetes Res Clin Pract"},{"issue":"11","key":"925_CR42","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1111\/dom.13818","volume":"21","author":"TS Bailey","year":"2019","unstructured":"Bailey TS, Wu J, Zhou FL, et al. Switching to insulin glargine 300 units\/mL in real-world older patients with type 2 diabetes (DELIVER 3). Diabetes Obes Metab. 2019;21(11):2384\u201393.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"925_CR43","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s13300-019-0568-8","volume":"10","author":"J Pettus","year":"2019","unstructured":"Pettus J, Roussel R, Zhou FL, et al. Rates of hypoglycemia predicted in patients with type 2 diabetes on insulin glargine 300 U\/ml versus first- and second-generation basal insulin analogs: the real-world LIGHTNING study. Diabetes Ther. 2019;10(2):617\u201333.","journal-title":"Diabetes Ther"},{"issue":"5","key":"925_CR44","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/dom.13199","volume":"20","author":"FL Zhou","year":"2018","unstructured":"Zhou FL, Ye F, Berhanu P, et al. Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units\/mL vs other basal insulins in patients with type 2 diabetes using basal insulin. Diabetes Obes Metab. 2018;20(5):1293\u20137.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"925_CR45","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1111\/dom.13793","volume":"21","author":"SD Sullivan","year":"2019","unstructured":"Sullivan SD, Nicholls CJ, Gupta RA, et al. Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units\/mL or insulin degludec: the DELIVER Naive D real-world study. Diabetes Obes Metab. 2019;21(9):2123\u201332.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"925_CR46","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1111\/dom.13693","volume":"21","author":"TS Bailey","year":"2019","unstructured":"Bailey TS, Zhou FL, Gupta RA, et al. Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units\/mL or 100 units\/mL: real-world results from the DELIVER Naive cohort study. Diabetes Obes Metab. 2019;21(7):1596\u2013605.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"925_CR47","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/jdi.12884","volume":"10","author":"Y Kawaguchi","year":"2019","unstructured":"Kawaguchi Y, Sawa J, Sakuma N, Kumeda Y. Efficacy and safety of insulin glargine 300 U\/mL vs insulin degludec in patients with type 2 diabetes: a randomized, open-label, cross-over study using continuous glucose monitoring profiles. J Diabetes Investig. 2019;10(2):343\u201351.","journal-title":"J Diabetes Investig"},{"issue":"4","key":"925_CR48","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s00125-019-05080-9","volume":"63","author":"A Philis-Tsimikas","year":"2020","unstructured":"Philis-Tsimikas A, Klonoff DC, Khunti K, et al. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial. Diabetologia. 2020;63(4):698\u2013710.","journal-title":"Diabetologia"},{"issue":"10","key":"925_CR49","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.2337\/dc18-0559","volume":"41","author":"J Rosenstock","year":"2018","unstructured":"Rosenstock J, Cheng A, Ritzel R, et al. More similarities than differences testing insulin glargine 300 units\/mL versus insulin degludec 100 units\/mL in insulin-naive type 2 diabetes: the randomized head-to-head BRIGHT trial. Diabetes Care. 2018;41(10):2147\u201354.","journal-title":"Diabetes Care"},{"issue":"2","key":"925_CR50","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/jdi.12894","volume":"10","author":"M Yamabe","year":"2019","unstructured":"Yamabe M, Kuroda M, Hirosawa Y, et al. Comparison of insulin glargine 300 U\/mL and insulin degludec using flash glucose monitoring: a randomized cross-over study. J Diabetes Investig. 2019;10(2):352\u20137.","journal-title":"J Diabetes Investig"},{"issue":"9","key":"925_CR51","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1111\/dom.13345","volume":"20","author":"SD Sullivan","year":"2018","unstructured":"Sullivan SD, Bailey TS, Roussel R, et al. Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: comparative effectiveness of insulin glargine 300 units\/mL and insulin degludec in the DELIVER D+ cohort study. Diabetes Obes Metab. 2018;20(9):2148\u201358.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"925_CR52","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/dom.13616","volume":"21","author":"J Tibaldi","year":"2019","unstructured":"Tibaldi J, Hadley-Brown M, Lieble A, et al. A comparative effectiveness study of degludec and insulin glargine 300 U\/mL in insulin-naive patients with type 2 diabetes. Diabetes Obes Metab. 2019;21(4):1001\u20139.","journal-title":"Diabetes Obes Metab."},{"key":"925_CR53","unstructured":"Centers for Disease Control and Prevention (CDC). National diabetes statistics report, 2017. Estimates of Diabetes and Its Burden in the United States. 2017. https:\/\/dev.diabetes.org\/sites\/default\/files\/2019-06\/cdc-statistics-report-2017.pdf. Accessed on June 1, 2020."},{"issue":"15","key":"925_CR54","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1001\/jama.2009.460","volume":"301","author":"RA Whitmer","year":"2009","unstructured":"Whitmer RA, Karter AJ, Yaffe K, Quesenberry Jr CP, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009;301(15):1565\u201372.","journal-title":"JAMA"},{"issue":"4","key":"925_CR55","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/00325481.2019.1578590","volume":"131","author":"J Freeman","year":"2019","unstructured":"Freeman J. Management of hypoglycemia in older adults with type 2 diabetes. Postgrad Med. 2019;131(4):241\u201350.","journal-title":"Postgrad Med"},{"issue":"11","key":"925_CR56","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.2337\/dc13-0523","volume":"36","author":"SR Majumdar","year":"2013","unstructured":"Majumdar SR, Hemmelgarn BR, Lin M, McBrien K, Manns BJ, Tonelli M. Hypoglycemia associated with hospitalization and adverse events in older people: population-based cohort study. Diabetes Care. 2013;36(11):3585\u201390.","journal-title":"Diabetes Care"},{"issue":"7","key":"925_CR57","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1001\/jamainternmed.2014.1824","volume":"174","author":"KJ Lipska","year":"2014","unstructured":"Lipska KJ, Ross JS, Wang J, et al. National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011. JAMA Intern Med. 2014;174(7):1116\u201324.","journal-title":"JAMA Intern Med"},{"issue":"1","key":"925_CR58","first-page":"23","volume":"17","author":"D Greco","year":"2004","unstructured":"Greco D, Angileri G. Drug-induced severe hypoglycaemia in Type 2 diabetic patients aged 80 years or older. Diabetes Nutr Metab. 2004;17(1):23\u20136.","journal-title":"Diabetes Nutr Metab"},{"issue":"3","key":"925_CR59","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2337\/diab.43.3.403","volume":"43","author":"GS Meneilly","year":"1994","unstructured":"Meneilly GS, Cheung E, Tuokko H. Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes. Diabetes. 1994;43(3):403\u201310.","journal-title":"Diabetes"},{"issue":"5","key":"925_CR60","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/(SICI)1096-9136(199805)15:5<398::AID-DIA595>3.0.CO;2-B","volume":"15","author":"AJ Jaap","year":"1998","unstructured":"Jaap AJ, Jones GC, McCrimmon RJ, Deary IJ, Frier BM. Perceived symptoms of hypoglycaemia in elderly type 2 diabetic patients treated with insulin. Diabet Med. 1998;15(5):398\u2013401.","journal-title":"Diabet Med"},{"issue":"2","key":"925_CR61","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2337\/diacare.20.2.135","volume":"20","author":"K Matyka","year":"1997","unstructured":"Matyka K, Evans M, Lomas J, Cranston I, Macdonald I, Amiel SA. Altered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy men. Diabetes Care. 1997;20(2):135\u201341.","journal-title":"Diabetes Care"},{"issue":"2","key":"925_CR62","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4158\/EP171922.OR","volume":"24","author":"MN Munshi","year":"2018","unstructured":"Munshi MN, Gill J, Chao J, Nikonova EV, Patel M. Insulin Glargine 300 U\/mL is associated with less weight gain while maintaining glycemic control and low risk of hypoglycemia compared with insulin glargine 100 U\/mL in an aging population with type 2 diabetes. Endocr Pract. 2018;24(2):143\u20139. \u00a0","journal-title":"Endocr Pract"},{"issue":"12","key":"925_CR63","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s40266-013-0128-2","volume":"30","author":"C Sorli","year":"2013","unstructured":"Sorli C, Warren M, Oyer D, Mersebach H, Johansen T, Gough SCL. Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trials. Drugs Aging. 2013;30(12):1009\u2013188.","journal-title":"Drugs Aging"},{"issue":"2","key":"925_CR64","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.diabet.2018.10.002","volume":"46","author":"JF Yale","year":"2020","unstructured":"Yale JF, Yale J-F, Aroda VR, et al. Glycaemic control and hypoglycaemia risk with insulin glargine 300 U\/mL versus glargine 100 U\/mL: a patient-level meta-analysis examining older and younger adults with type 2 diabetes. Diabetes Metab. 2020;46(2):110\u20138.","journal-title":"Diabetes Metab."},{"issue":"8","key":"925_CR65","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.2337\/dc18-0168","volume":"41","author":"R Ritzel","year":"2018","unstructured":"Ritzel R, Harris SB, Baron H, et al. A randomized controlled trial comparing efficacy and safety of insulin glargine 300 units\/mL versus 100 units\/mL in older people with type 2 diabetes: results from the SENIOR study. Diabetes Care. 2018;41(8):1672\u201380.","journal-title":"Diabetes Care"},{"issue":"7","key":"925_CR66","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1111\/dom.13708","volume":"21","author":"SR Heller","year":"2019","unstructured":"Heller SR, Devries JH, Wysham C, et al. Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: results from SWITCH 2. Diabetes Obes Metab. 2019;21(7):1634\u201341.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"925_CR67","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1111\/dom.13699","volume":"21","author":"RE Pratley","year":"2019","unstructured":"Pratley RE, Emerson SS, Franek E, et al. Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: results from DEVOTE (DEVOTE 7). Diabetes Obes Metab. 2019;21(7):1625\u201333.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"925_CR68","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.2215\/CJN.00800209","volume":"4","author":"MF Moen","year":"2009","unstructured":"Moen MF, Zhan M, Zhu VD, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1121\u20137.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"925_CR69","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1111\/dom.13470","volume":"20","author":"F Javier Escalada","year":"2018","unstructured":"Javier Escalada F, Halimi S, Senior PA, et al. Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U\/mL extend to people with type 2 diabetes and mild-to-moderate renal impairment. Diabetes Obes Metab. 2018;20(12):2860\u20138.","journal-title":"Diabetes Obes Metab"},{"key":"925_CR70","doi-asserted-by":"crossref","unstructured":"Haluzik M, Cheng A, M\u00fcller-Wieland D, et al. Differential glycaemic control with basal insulin glargine 300 U\/mL versus degludec 100 U\/mL according to kidney function in type 2 diabetes\u2014a subanalysis from the BRIGHT trial. Diabetes Obes Metab. 2020;22(8):1369\u201337.","DOI":"10.1111\/dom.14043"},{"issue":"3","key":"925_CR71","doi-asserted-by":"crossref","first-page":"e00073","DOI":"10.1002\/edm2.73","volume":"2","author":"FL Zhou","year":"2019","unstructured":"Zhou FL, Nicholls C, Lin X, et al. Hypoglycaemia and treatment patterns among insulin-treated patients with type 2 diabetes who switched to insulin glargine 300 units\/mL versus other basal insulin in a real-world setting. Endocrinol Diabetes Metab. 2019;2(3):e00073.","journal-title":"Endocrinol Diabetes Metab"},{"key":"925_CR72","first-page":"8","volume":"12","author":"DC Henao-Carrillo","year":"2018","unstructured":"Henao-Carrillo DC, Mu\u00f1oz OM, G\u00f3mez AM, et al. Reduction of glycemic variability with Degludec insulin in patients with unstable diabetes. J Clin Transl Endocrinol. 2018;12:8\u201312.","journal-title":"J Clin Transl Endocrinol"},{"key":"925_CR73","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837\u201353.","DOI":"10.1016\/S0140-6736(98)07019-6"},{"issue":"8","key":"925_CR74","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1615692","volume":"377","author":"SP Marso","year":"2017","unstructured":"Marso SP, MGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377(8):723\u201332.","journal-title":"N Engl J Med"},{"issue":"1","key":"925_CR75","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12933-019-0960-8","volume":"18","author":"RE Pratley","year":"2019","unstructured":"Pratley RE, Husain M, Lingvay I, et al. Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14. Cardiovasc Diabetol. 2019;18(1):156.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"925_CR76","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s13300-019-00715-x","volume":"11","author":"A Amod","year":"2020","unstructured":"Amod A, Buse BJ, McGuire DK, et al. Glomerular filtration rate and associated risks of cardiovascular events, mortality, and severe hypoglycemia in patients with type 2 diabetes: secondary analysis (DEVOTE 11). Diabetes Ther. 2020;11(1):53\u201370.","journal-title":"Diabetes Ther"},{"issue":"4","key":"925_CR77","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","volume":"367","author":"HC Gerstein","year":"2012","unstructured":"Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319\u201328.","journal-title":"N Engl J Med"},{"issue":"7","key":"925_CR78","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/nm.4350","volume":"23","author":"MP Czech","year":"2017","unstructured":"Czech MP. Insulin action and resistance in obesity and type 2 diabetes. Nat Med. 2017;23(7):804\u201314.","journal-title":"Nat Med"},{"issue":"6","key":"925_CR79","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2337\/diacare.18.6.747","volume":"18","author":"KW Chen","year":"1995","unstructured":"Chen KW, Boyko EJ, Bergstrom RW, et al. Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM. 5-year follow-up of initially nondiabetic Japanese-American men. Diabetes Care. 1995;18(6):747\u201353.","journal-title":"Diabetes Care"},{"issue":"4","key":"925_CR80","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/dom.12619","volume":"18","author":"M Matsuhisa","year":"2016","unstructured":"Matsuhisa M, Koyama M, Cheng X, et al. New insulin glargine 300 U\/ml versus glargine 100 U\/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1). Diabetes Obes Metab. 2016;18(4):375\u201383.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"925_CR81","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2337\/cd18-0016","volume":"37","author":"L Chaykin","year":"2019","unstructured":"Chaykin L, Bhargava A, de la Rosa R, et al. Effect of insulin degludec versus insulin glargine U100 on hypoglycemia in Hispanic patients with type 2 diabetes: results from the SWITCH 2 trial. Clin Diabetes. 2019;37(1):73\u201381.","journal-title":"Clin Diabetes"},{"key":"925_CR82","doi-asserted-by":"publisher","unstructured":"Thewjitcharoen Y, Yenseung N, Malidaeng A, et al. Effectiveness of insulin degludec in Thai patients with diabetes mellitus: real-world evidence from a Specialized Diabetes Center. Exp Clin Endocrinol Diabetes. 2019. https:\/\/doi.org\/10.1055\/a-0899-5118.","DOI":"10.1055\/a-0899-5118"},{"issue":"4","key":"925_CR83","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s13300-019-0654-y","volume":"10","author":"Y Kawaguchi","year":"2019","unstructured":"Kawaguchi Y, Sawa J, Hamai C, et al. Differential effect of hypoalbuminemia on hypoglycemia on type 2 diabetes patients treated with insulin glargine 300 U\/ml and insulin degludec. Diabetes Ther. 2019;10(4):1535\u201341.","journal-title":"Diabetes Ther."},{"issue":"6","key":"925_CR84","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.2337\/dc19-1940","volume":"43","author":"FJ Pasquel","year":"2020","unstructured":"Pasquel FJ, Lansang MC, Khowaja A, et al. A randomized controlled trial comparing glargine U300 and glargine U100 for the inpatient management of medicine and surgery patients with type 2 diabetes: glargine U300 hospital trial. Diabetes Care. 2020;43(6):1242\u20138.","journal-title":"Diabetes Care"},{"issue":"3","key":"925_CR85","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s13300-018-0419-z","volume":"9","author":"F Okajima","year":"2018","unstructured":"Okajima F, Nakamura Y, Yamaguchi Y, et al. Basal-bolus insulin therapy with Gla-300 during hospitalization reduces nocturnal hypoglycemia in patients with type 2 diabetes mellitus: a randomized controlled study. Diabetes Ther. 2018;9(3):1049\u201359.","journal-title":"Diabetes Ther"},{"issue":"11","key":"925_CR86","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1507\/endocrj.EJ18-0309","volume":"66","author":"J Suzuki","year":"2019","unstructured":"Suzuki J, Yamakawa T, Oba M, et al. Efficacy and safety of insulin degludec U100 and insulin glargine U100 in combination with meal-time bolus insulin in hospitalized patients with type 2 diabetes: an open-label, randomized controlled study. Endocr J. 2019;66(11):971\u201382.","journal-title":"Endocr J"},{"issue":"12","key":"925_CR87","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1507\/endocrj.EJ16-0252","volume":"63","author":"Y Nagai","year":"2016","unstructured":"Nagai Y, Murakami M, Igarashi K, et al. Efficacy and safety of thrice-weekly insulin degludec in elderly patients with type 2 diabetes assessed by continuous glucose monitoring. Endocr J. 2016;63(12):1099\u2013106.","journal-title":"Endocr J"},{"issue":"1","key":"925_CR88","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12955-018-0883-1","volume":"16","author":"J Weatherall","year":"2018","unstructured":"Weatherall J, Polonsky WH, Lanar S, et al. When insulin degludec enhances quality of life in patients with type 2 diabetes: a qualitative investigation. Health Qual Life Outcomes. 2018;16(1):87.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"925_CR89","doi-asserted-by":"crossref","first-page":"e000548","DOI":"10.1136\/bmjdrc-2018-000548","volume":"6","author":"TH Wieringa","year":"2018","unstructured":"Wieringa TH, de Wit M, Twisk JW, et al. Improved diabetes medication convenience and satisfaction in persons with type 2 diabetes after switching to insulin glargine 300 U\/mL: results of the observational OPTIN-D study. BMJ Open Diabetes Res Care. 2018;6(1):e000548.","journal-title":"BMJ Open Diabetes Res Care."},{"key":"925_CR90","doi-asserted-by":"crossref","first-page":"108189","DOI":"10.1016\/j.diabres.2020.108189","volume":"166","author":"M Hassanein","year":"2020","unstructured":"Hassanein M, Buyukbese MA, Malek R, et al. Real-world safety and effectiveness of insulin glargine 300 U\/mL in participants with type 2 diabetes who fast during Ramadan: the observational ORION study. Diabetes Res Clin Pract. 2020;166:108189.","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"925_CR91","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1089\/dia.2016.0454","volume":"19","author":"I Lingvay","year":"2017","unstructured":"Lingvay I, Chao J, Dalal MR, et al. Efficacy and safety of insulin glargine 300 U\/mL versus insulin glargine 100 U\/mL in high-risk and low-risk patients with type 2 diabetes stratified using common clinical performance measures. Diabetes Technol Ther. 2017;19(5):315\u201322.","journal-title":"Diabetes Technol Ther."}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-020-00925-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-020-00925-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-020-00925-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,8]],"date-time":"2023-10-08T06:43:52Z","timestamp":1696747432000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-020-00925-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,25]]},"references-count":91,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["925"],"URL":"https:\/\/doi.org\/10.1007\/s13300-020-00925-8","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"type":"print","value":"1869-6953"},{"type":"electronic","value":"1869-6961"}],"subject":[],"published":{"date-parts":[[2020,9,25]]},"assertion":[{"value":"3 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}